Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors
Abstract KRAS mutations represent the most common driver genetic alterations in multiple malignant tumors, particularly exerting well-defined oncogenic driver roles in non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The recent success of KRAS G12C mutation-specif...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer
2025-10-01
|
| Collection: | Discover Oncology |
| Sujets: | |
| Accès en ligne: | https://doi.org/10.1007/s12672-025-03569-x |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|